We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Radiomics Predicts Patient Benefits from Chemotherapy

By MedImaging International staff writers
Posted on 04 Apr 2019
Print article
Image: Radiomic feature maps show differences between lesions in responders and nonresponders at pretreatment CT (Photo courtesy of Cleveland Clinic).
Image: Radiomic feature maps show differences between lesions in responders and nonresponders at pretreatment CT (Photo courtesy of Cleveland Clinic).
Data retrieved from computed tomography (CT) images may be able to forecast which lung cancer patients will respond to chemotherapy, claims a new study.

Researchers at Case Western Reserve University (CWRU; Cleveland, OH, USA), the Cleveland Clinic (CC; OH, USA), and other institutions retrospectively analyzed data from 125 patients with non–small cell lung cancer (NSCLC) who had been treated with pemetrexed-based platinum doublet chemotherapy, in order to identify the role of radiomics texture features--both within and outside the nodule--in predicting time to progression (TTP), overall survival (OS), and response to chemotherapy.

The patients were divided randomly into two sets, with the constraint that there were an equal number of responders and nonresponders in the training set. The training set comprised 53 patients with NSCLC, and the validation set comprised 72 patients. A machine learning classifier trained with radiomic texture features extracted from intra- and peritumoral regions of non–contrast-enhanced CT images was used to predict response to chemotherapy. The radiomic risk-score signature was generated by using least absolute shrinkage and selection operator, and association of the radiomic signature with TTP and OS was also evaluated.

The results showed that radiomic features derived from within the tumor and from the area around the tumor were able to distinguish between patients who responded to chemotherapy and those who did not with an accuracy of 0.77. In addition, the radiomic features predicted TTP and OS, and decision curve analysis demonstrated that in terms of clinical usefulness, the radiomics signature had a higher overall net benefit in prediction of high-risk patients to receive treatment than clinical-pathologic measurements. The study was published on March 20, 2019, in Radiology: Artificial Intelligence.

“This is the first study to demonstrate that computer-extracted patterns of heterogeneity, or diversity, from outside the tumor were predictive of response to chemotherapy,” said co-lead author Monica Khunger, MD, of the CC. “This is very critical because it could allow for predicting in advance of therapy which patients with lung cancer are likely to respond or not. This could help identify patients who are likely to not respond to chemotherapy for alternative therapies such as radiation or immunotherapy.”

Radiomics is an extension of computer-aided diagnosis, and refers to the comprehensive quantification of tumor phenotypes by extracting a large number of quantitative image features for data mining and precision medicine. In recent years radiomics has successfully extracted a variety of clinically relevant features, merging them into signatures, in order to estimate the probability of malignancy of identified breast cancer lesions.

Related Links:
Case Western Reserve University
Cleveland Clinic

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
C-Arm with FPD
Digiscan V20 / V30
New
Portable Radiology System
DRAGON ELITE & CLASSIC
New
Portable X-Ray Unit
AJEX240H

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.